259 related articles for article (PubMed ID: 23593132)
1. Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates.
de Tullio MB; Castelletto V; Hamley IW; Martino Adami PV; Morelli L; Castaño EM
PLoS One; 2013; 8(4):e59113. PubMed ID: 23593132
[TBL] [Abstract][Full Text] [Related]
2. Quantitative NMR Study of Insulin-Degrading Enzyme Using Amyloid-β and HIV-1 p6 Elucidates Its Chaperone Activity.
Ramaraju B; Nelson SL; Zheng W; Ghirlando R; Deshmukh L
Biochemistry; 2021 Aug; 60(33):2519-2523. PubMed ID: 34342986
[TBL] [Abstract][Full Text] [Related]
3. The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective.
de Tullio MB; Morelli L; Castaño EM
Prion; 2008; 2(2):51-6. PubMed ID: 19098445
[TBL] [Abstract][Full Text] [Related]
4. Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization.
Chesneau V; Vekrellis K; Rosner MR; Selkoe DJ
Biochem J; 2000 Oct; 351 Pt 2(Pt 2):509-16. PubMed ID: 11023838
[TBL] [Abstract][Full Text] [Related]
5. Degradation of Alzheimer's Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme.
Sahoo BR; Panda PK; Liang W; Tang WJ; Ahuja R; Ramamoorthy A
J Mol Biol; 2021 Jun; 433(13):166993. PubMed ID: 33865867
[TBL] [Abstract][Full Text] [Related]
6. Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy.
Morelli L; Llovera RE; Mathov I; Lue LF; Frangione B; Ghiso J; Castaño EM
J Biol Chem; 2004 Dec; 279(53):56004-13. PubMed ID: 15489232
[TBL] [Abstract][Full Text] [Related]
7. The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis.
Llovera RE; de Tullio M; Alonso LG; Leissring MA; Kaufman SB; Roher AE; de Prat Gay G; Morelli L; Castaño EM
J Biol Chem; 2008 Jun; 283(25):17039-48. PubMed ID: 18411275
[TBL] [Abstract][Full Text] [Related]
8. Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme.
McCord LA; Liang WG; Dowdell E; Kalas V; Hoey RJ; Koide A; Koide S; Tang WJ
Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13827-32. PubMed ID: 23922390
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering.
Sandberg A; Luheshi LM; Söllvander S; Pereira de Barros T; Macao B; Knowles TP; Biverstål H; Lendel C; Ekholm-Petterson F; Dubnovitsky A; Lannfelt L; Dobson CM; Härd T
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15595-600. PubMed ID: 20713699
[TBL] [Abstract][Full Text] [Related]
10. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.
Qiu WQ; Walsh DM; Ye Z; Vekrellis K; Zhang J; Podlisny MB; Rosner MR; Safavi A; Hersh LB; Selkoe DJ
J Biol Chem; 1998 Dec; 273(49):32730-8. PubMed ID: 9830016
[TBL] [Abstract][Full Text] [Related]
11. Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease.
Fernández-Gamba A; Leal MC; Morelli L; Castaño EM
Curr Pharm Des; 2009; 15(31):3644-55. PubMed ID: 19925417
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the Activity of the Insulin-Degrading Enzyme by Aβ Peptides.
Kemeh MM; Lazo ND
ACS Chem Neurosci; 2023 Aug; 14(16):2935-2943. PubMed ID: 37498802
[TBL] [Abstract][Full Text] [Related]
13. Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.
Song ES; Juliano MA; Juliano L; Hersh LB
J Biol Chem; 2003 Dec; 278(50):49789-94. PubMed ID: 14527953
[TBL] [Abstract][Full Text] [Related]
14. Catalytic Mechanism of Amyloid-β Peptide Degradation by Insulin Degrading Enzyme: Insights from Quantum Mechanics and Molecular Mechanics Style Møller-Plesset Second Order Perturbation Theory Calculation.
Lai R; Tang WJ; Li H
J Chem Inf Model; 2018 Sep; 58(9):1926-1934. PubMed ID: 30133282
[TBL] [Abstract][Full Text] [Related]
15. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
[TBL] [Abstract][Full Text] [Related]
16. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.
Im H; Manolopoulou M; Malito E; Shen Y; Zhao J; Neant-Fery M; Sun CY; Meredith SC; Sisodia SS; Leissring MA; Tang WJ
J Biol Chem; 2007 Aug; 282(35):25453-63. PubMed ID: 17613531
[TBL] [Abstract][Full Text] [Related]
17. Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides.
Kurochkin IV; Guarnera E; Wong JH; Eisenhaber F; Berezovsky IN
Biochemistry; 2017 Jan; 56(1):228-239. PubMed ID: 27982586
[TBL] [Abstract][Full Text] [Related]
18. Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme.
Morelli L; Llovera R; Gonzalez SA; Affranchino JL; Prelli F; Frangione B; Ghiso J; Castano EM
J Biol Chem; 2003 Jun; 278(26):23221-6. PubMed ID: 12695513
[TBL] [Abstract][Full Text] [Related]
19. Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.
Stefanidis L; Fusco ND; Cooper SE; Smith-Carpenter JE; Alper BJ
Biochemistry; 2018 Aug; 57(32):4903-4914. PubMed ID: 30004674
[TBL] [Abstract][Full Text] [Related]
20. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
Shen Y; Joachimiak A; Rosner MR; Tang WJ
Nature; 2006 Oct; 443(7113):870-4. PubMed ID: 17051221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
